D-0265-2022 Class II Terminated
FDA drug recall D-0265-2022 was initiated by Pfizer Inc. on Nov 30, 2021 and is designated Class II. Reason for recall: Lack of sterility assurance: bag has the potential to leak. The recall status is terminated (terminated Jul 12, 2023). Affected quantity: 765 bags.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 8, 2021
- Initiation Date
- Nov 30, 2021
- Termination Date
- Jul 12, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 765 bags
Product description
5% Dextrose Injection, USP, 50 mL ADD-Vantage Unit, Rx only, Distributed by Hospira, INC., Lake Forest, IL 60045 USA, NDC 0409-7100-68/0409-7100-66
Reason for recall
Lack of sterility assurance: bag has the potential to leak.
Distribution pattern
USA Nationwide
Code information
Lot: 4923608 Exp. 1MAY2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0265-2022
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.